Experiences With the Valiant Thoracic Endograft

Evolved from the Talent, this new device design improves trackability and enables a lower force of deployment.

By Matt Thompson, MD, and Rob Morgan, MD

In the United Kingdom, endovascular treatment of the thoracic aorta is becoming established as a first-line treatment for pathological conditions affecting the distal arch and descending thoracic aorta. The pathology affecting the thoracic aorta is complex and adds to the challenges that must be faced with thoracic endografting. Common conditions now treated with endovascular techniques include thoracic aneurysms, dissections, and transections. As experience with thoracic endografting grows, the case mix has become increasingly complex, with the indications for thoracic endovascular procedures expanding. It is now common to treat pathological lesions affecting the mid arch, to use hybrid approaches to treat thoracoabdominal aneurysms, to treat patients with a ruptured thoracic aorta, and to attempt repair of lesions with unfavorable anatomy.

In general, it is true to say that endograft design and manufacture has not kept pace with clinical ambition in the thoracic aorta, particularly as many thoracic endografts have been modified from infrarenal devices in which the anatomical challenges are different. This has often resulted in considerable technical difficulty when attempting to treat complex thoracic diseases with first-generation thoracic endografts. Common problems include:

• The ability of relatively rigid thoracic endografts to conform to the anatomy of the aortic arch. Graft nonconformity may lead to a graft sitting proudly in the aortic arch with subsequent instability and graft failure.
• The ability of long delivery systems to track through tortuous, calcified vessels.
• The ability of current stents to provide secure fixation and long-term graft durability.
• Inaccurate deployment leading to great vessel occlusion or a proximal endoleak.
• High forces of deployment resulting in inaccurate positioning or the necessity for repeated manipulation and brachial wires.
• The same graft type being used for both thoracic aneurysms and dissections despite the grossly different pathologies and desired outcomes.


In response to the challenges of the thoracic aorta, Medtronic introduced the Valiant thoracic endograft into clinical practice outside the US in 2005. The Valiant is an evolution from the Talent thoracic endograft and contains improved design features including modifications to stent design, delivery sheath, graft configuration, deployment methodology, and markers.

Some of the most significant changes to the Valiant graft include:

• An eight-peak spring to provide proximal fixation. This allows better apposition to the vessel and distributes the radial force over more apices.
• Both closed-web and open-web options may be tailored to the particular thoracic pathology

(Figure 1A).
• No connecting bar allows greater flexibility of the main endograft (Figure 1B).
• More choices in graft selection and longer lengths available (up to 227 mm).
• Improved graft cover design leading to less stretching, improved trackability, and lower force of deployment.
• Integrated handle for deployment (same platform as the Talent AAA stent graft) provides a mechanical advantage and a lower user-experienced deployment force.
The Valiant stent graft is available in lengths ranging from 100 mm to 227 mm, and in diameters ranging from 24 mm to 46 mm. Both straight and tapered grafts are available.


The first cases using this device were performed at St. George’s Hospital in London. Since then, the Valiant graft has been introduced across Europe, and more than 1,000 grafts have been implanted in 700 patients. The St. George’s experience includes 58 grafts in 32 patients. The technical success in our personal series is 100%, but midterm data are not yet available. Currently, a retrospective study is underway to define the early and midterm results of the Valiant graft. A prospective registry is planned to define technical success in placement and midterm outcome.

Initial clinical observations have confirmed the promise of the Valiant graft in the treatment of thoracic aortic pathology. The delivery system allows tracking of the device through tortuous vessels and enables placement in the proximal arch without impacting on the aortic valve. The deployment has been made significantly easier with the integrated mechanical handle such that the user-experienced force is significantly reduced and accurate deployment is possible in most situations. Removal of the connecting bar allows conformation to acutely angled aortic arches (Figures 2 through 4). The closed-web system allows different proximal configurations to be trialled in different disease states. Several centers have used the closed-web design to preferentially treat Type B dissections. This has proved possible in the descending thoracic aorta, but the closed web should not presently be utilized in the arch due to the hemodynamic forces involved.

Early experience suggests that technical success of the Valiant graft is high and that there are significant advantages to this design. Clearly, carefully documented prospective evidence of efficacy is now needed. 

Matt Thompson, MD, is a Professor of Surgery at St. George’s Vascular Institute, London, England. He is a paid consult to Medtronic. He may be reached at 44 208 725 3205; matt.thompson@stgeorges.nhs.uk.
Rob Morgan, FRCR, is a Consultant Interventional Radiologist at St. George’s Hospital, London, England. He is a paid consult to Medtronic. Dr. Morgan may be reached at robert.morgan@stgeorges.nhs.uk.

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.